Abstract
The purpose of this study was to assess whether antidepressant prescribing during pregnancy decreased following release of U.S. and Canadian public health advisory warnings about the risk of perinatal complications with antidepressants. We analyzed data from 228,876 singleton pregnancies among women (aged 15–44 years) continuously enrolled in Tennessee Medicaid with full pharmacy benefits (1995–2007). Antidepressant prescribing was determined through outpatient pharmacy dispensing files. Information on sociodemographic and clinical factors was obtained from enrollment files and linked birth certificates. An interrupted time series design with segmented regression analysis was used to quantify the impact of the advisory warnings (2002–2005). Antidepressant prescribing rates increased steadily from 1995 to 2001, followed by sharper increases from 2002 to late 2004. Overall antidepressant prescribing prevalence was 34.51 prescriptions [95 % confidence interval (CI) 33.37–35.65] per 1,000 women in January 2002, and increased at a rate of 0.46 (95 % CI 0.41–0.52) prescriptions per 1,000 women per month until the end of the pre-warning period (May 2004). During the post-warning period (October 2004–June 2005), antidepressant prescribing decreased by 1.48 (95 % CI 1.62–1.35) prescriptions per 1,000 women per month. These trends were observed for both selective serotonin reuptake inhibitors (SSRI) and non-SSRI antidepressants, although SSRI prescribing decreased at a greater rate. We conclude that antidepressant prescribing to pregnant women in Tennessee Medicaid increased from 1995 to late 2004. U.S. and Canadian public health advisories about antidepressant-associated perinatal complications were associated with steady decreases in antidepressant prescribing from late 2004 until the end of the study period, suggesting that the advisory warnings were impactful on antidepressant prescribing in pregnancy.
Similar content being viewed by others
References
‘t Jong GW, Einarson T, Koren G, Einarson A (2012) Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review. Reprod Toxicol 34:293–97
Alder J, Fink N, Bitzer J, Hosli I, Holzgreve W (2007) Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 20:189–209
Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM (2008) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684–2692
Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198:194–195
Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65:600–606
Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ (2002) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43
Becker RA, Chambers JM, Wilks AR (1988) The New S Language. Wadsworth & Brooks/Cole.
Bilszta JL, Tsuchiya S, Han K, Buist AE, Einarson A (2011) Primary care physician’s attitudes and practices regarding antidepressant use during pregnancy: a survey of two countries. Arch Womens Ment Health 14:71–75
Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G (2004) Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49:726–35
Canada H (2004) Health Canada advises of potential serious adverse effects of SSRIs and other antidepressants on newborns [advisory]. Health Canada, Ottawa
Canadian Psychiatric Association (2006) Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 51:9S–91S
Cleveland WS (1979) Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829–36
Cleveland WS (1981) LOWESS: a program for smoothing scatterplots by robust locally weighted regression. The American Statistician 35:54
Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499–507
Committee on Safety of Medicines’ Expert Working Group (2003) Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitor antidepressants. http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf. Accessed 22 Aug 2013
Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196:544–45
Davalos DB, Yadon CA, Tregellas HC (2012) Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health 15:1–14
Davidson JR (2010) Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry E1:e04
Food and Drug Administration (2004) FDA statement on recommendations of the psychopharmacologic drugs and pediatric advisory committees. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108352.htm. Accessed 22 Aug 2013
Einarson TR, Einarson A (2005) Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 14:823–27
Einarson A, Schachtschneider AK, Halil R, Bollano E, Koren G (2005) SSRI’S and other antidepressant use during pregnancy and potential neonatal adverse effects: impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy Childbirth 5:11
Hayes RM, Wu P, Shelton RC, Cooper WO, Dupont WD, Mitchel E, Hartert TV (2012) Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol 207:49.e1–9
Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR (2005) Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 39:803–09
Huybrechts KF, Palmsten K, Mogun H, Kowal M, Avorn J, Steoguchi-Iwata S, Hernandez-Diaz S (2013) National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry 35:265–71
Ipser JC, Stein DJ (2012) Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol 15:825–40
Johnson RE, Vollmer WM (1991) Comparing sources of drug data about the elderly. J Am Geriatr Soc 39:1079–84
Karpel JP, Peters JI, Szema AM, Smith B, Anderson PJ (2009) Differences in physicians’ self-reported knowledge of, attitudes toward, and responses to the black box warning on long-acting beta-agonists. Ann Allergy Asthma Immunol 103:304–10
Koren G, Nordeng H (2012) Antidepressant use during pregnancy: the benefit–risk ratio. Am J Obstet Gynecol 207:157–63
Kroenke K, Krebs EE, Bair MJ (2009) Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 31:206–19
Kuehn BM (2009) No easy answers for physicians caring for pregnant women with depression. JAMA 302(2413–4):2420
Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV, Canadian Network for Mood and Anxiety Treatments (CANMAT) (2009) Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117(Suppl 1):S26–S43
Landry JA, Smyer MA, Tubman JG, Lago DJ, Roberts J, Simonson W (1988) Validation of two methods of data collection of self-reported medicine use among the elderly. Gerontologist 28:672–76
Lanni C, Gonovi S, Lucchelli A, Boselli C (2009) Depression and antidepressants: molecular and cellular aspects. Cell Mol Life Sci 66:2985–3008
Lindahl V, Pearson JL, Colpe L (2005) Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health 8:77–87
Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA (2007) First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675–83
Lyerly AD, Mitchell LM, Armstrong EM, Harris LH, Kukla R, Kuppermann M, Little MO (2007) Risks, values, and decision making surrounding pregnancy. Obstet Gynecol 109:979–84
Milgrom J, Gemmill AW, Bilszta JL, Hayes B, Barnett B, Brooks J, Ericksen J, Ellwood D, Buist A (2008) Antenatal risk factors for postnatal depression: a large prospective study. J Affect Disord 108:147–57
Olfson MM, Marcus SC (2009) National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66:848–56
Olfson M, Marcus SC, Druss BG (2008) Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 65:94–101
Payne JL, Meltzer-Brody S (2009) Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol 52:469–82
Ramos E, Oraichi D, Rey E, Blais L, Berard A (2007) Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 114:1055–64
Ray WA (1997) Policy and program analysis using administrative databases. Ann Intern Med 127:712–18
Ray WA, Griffin MR (1989) Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 129:837–49
Ricci JR, Coulen C, Berger JE, Moore MC, McQueen A, Jan SA (2009) Prescriber compliance with black box warnings in older adult patients. Am J Manag Care 15:e103–e108
Sclar DA, Robison LM, Castillo LV, Schmidt JM, Bowen KA, Oganov AM, Skaer TL, Kogut SJ (2012) Concomitant use of triptan, and SSRI or SNRI after the US food and drug administration alert on serotonin syndrome. Headache 52:198–203
Shadish WR, Cook TD, Campbell T (2002) Experimental and quasi-experimental designs for generalized causal inference. Houghton Mifflin, Boston
U.S. Food and Drug Authority (2004) FDA Medwatch drug alert on Effexor and SSRIs. 6-3-2004.
Udechuku A, Nguyen T, Hill R, Szego K (2010) Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 44:978–96
Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den B, Egberts T (2006) Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62:863–70
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27:299–309
West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142:1103–12
Wichman CL, Fothergill A, Moore KM, Lang TR, Heise RH Jr, Watson WJ (2008) Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol 28:714–16
Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL (2004) Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry 161:1290–92
Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT (2009a) Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 166:557–66
Wisner KL, Appelbaum PS, Uhl K, Goldkind SF (2009b) Pharmacotherapy for depressed pregnant women: overcoming obstacles to gathering essential data. Clin Pharmacol Ther 86:362–65
World Health Organization (1989) The health of youth. Geneva: World Health Organization. Report No.: Document 399 A42/Technical Discussions/2.
Wurst KE, Poole C, Ephross SA, Olshan AF (2010) First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 88:159–70
Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C (2009) The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 114:703–13
Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K, Brunetto WL, Lin H, Burkman RT, Zolop CM, Lockwood CJ (2011) Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 22:848–54
Financial support/disclosures
This work was supported by grants from the National Institutes of Health K24 AI77930U01, HL 072471, RC4 MH092755, and R03 MH088902. R.C.S. received research funding from Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Forest Pharmaceuticals, Janssen Pharmaceutica, Novartis Pharmaceuticals, Otsuka Pharmaceuticals, Pamlab, Pfizer, Repligen, and St. Jude Medical. R.C.S. has consulted for Eli Lilly and Company, Cyberonics, Evotec AG, Forest Pharmaceuticals, Gideon Richter PLC, Janssen Pharmaceutica, Medronic, Otsuka Pharmaceuticals, Pamlab, Inc, Pfizer, Repligen, and Sierra Neuropharmaceuticals. The remaining authors report no conflict of interest. We are indebted to the Tennessee Bureau of TennCare of the Department of Finance and Administration, and the Tennessee Department of Health, Office of Policy, Planning & Assessment, for providing the data on the TennCare cohort.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bobo, W.V., Epstein, R.A., Hayes, R.M. et al. The effect of regulatory advisories on maternal antidepressant prescribing, 1995–2007: an interrupted time series study of 228,876 pregnancies. Arch Womens Ment Health 17, 17–26 (2014). https://doi.org/10.1007/s00737-013-0383-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00737-013-0383-6